FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2053980003> ?p ?o ?g. }

• W2053980003 endingPage "722" @default.
• W2053980003 startingPage "719" @default.
• W2053980003 abstract "Bisphosphonates (BPs) are potent drugs, used in metastatic cancer-like prostate or breast carcinoma. In recent studies, besides reduced bone remodeling, influences on angiogenesis and neovascularization were reported. Since BPs have the tendency to accumulate in the bones, the biological effect of various nitrogen- and non-nitrogen BPs on endothelial progenitor cells (EPCs) that originated from bone marrow and mobilized under physiological and pathophysiological conditions, such as tumor neovascularization, was investigated. EPCs subsequent to 72‑h treatment with different concentrations of bisphosphonates comprised the non-nitrogen-containing BP clodronate and the nitrogen-containing BPs ibandronate, pamidronate and zoledronate. After incubation, biological activity was measured by using the migration boyden chamber assay and measurement of the colony-forming ability. Nitrogen-containing BPs inhibited the migration ability and differentiation of EPCs in a dose-dependent manner, as compared to the non-treated control groups. More specifically, the nitrogen-containing BP zoledronate significantly inhibited angiogenesis and neovascularization. Clodronate was less distinct on EPC function. To underline the importance of neovascularization in the context of tumor angiogenesis, EPC functions were significantly influenced in a dose-dependent manner by nitrogen-containing BPs. From these findings, we conclude that especially the nitrogen-containing BPs, such as zoledronate, are potential anticancer agents through the inhibition of neovascularization." @default.
• W2053980003 created "2016-06-24" @default.
• W2053980003 creator A5016648702 @default.
• W2053980003 creator A5017361094 @default.
• W2053980003 creator A5018369709 @default.
• W2053980003 creator A5026574662 @default.
• W2053980003 creator A5054075776 @default.
• W2053980003 creator A5061574089 @default.
• W2053980003 creator A5064306593 @default.
• W2053980003 creator A5086646925 @default.
• W2053980003 date "2013-07-22" @default.
• W2053980003 modified "2023-09-29" @default.
• W2053980003 title "Investigation of inhibitory effects on EPC-mediated neovascularization by different bisphosphonates for cancer therapy" @default.
• W2053980003 cites W1965511198 @default.
• W2053980003 cites W1967035072 @default.
• W2053980003 cites W1975107690 @default.
• W2053980003 cites W1975761386 @default.
• W2053980003 cites W1984131196 @default.
• W2053980003 cites W199468027 @default.
• W2053980003 cites W2004346157 @default.
• W2053980003 cites W2039175323 @default.
• W2053980003 cites W2039656447 @default.
• W2053980003 cites W2053704719 @default.
• W2053980003 cites W2058843516 @default.
• W2053980003 cites W2077516839 @default.
• W2053980003 cites W2079719543 @default.
• W2053980003 cites W2088680847 @default.
• W2053980003 cites W2095936520 @default.
• W2053980003 cites W2099108029 @default.
• W2053980003 cites W2112711017 @default.
• W2053980003 cites W2129988610 @default.
• W2053980003 cites W2140725738 @default.
• W2053980003 cites W2142226770 @default.
• W2053980003 cites W2144860907 @default.
• W2053980003 cites W2145639716 @default.
• W2053980003 cites W2161962336 @default.
• W2053980003 cites W4242024627 @default.
• W2053980003 cites W4252851641 @default.
• W2053980003 doi "https://doi.org/10.3892/br.2013.145" @default.
• W2053980003 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3917058" @default.
• W2053980003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24649016" @default.
• W2053980003 hasPublicationYear "2013" @default.
• W2053980003 type Work @default.
• W2053980003 sameAs 2053980003 @default.
• W2053980003 citedByCount "13" @default.
• W2053980003 countsByYear W20539800032014 @default.
• W2053980003 countsByYear W20539800032015 @default.
• W2053980003 countsByYear W20539800032016 @default.
• W2053980003 countsByYear W20539800032018 @default.
• W2053980003 countsByYear W20539800032019 @default.
• W2053980003 countsByYear W20539800032020 @default.
• W2053980003 countsByYear W20539800032022 @default.
• W2053980003 countsByYear W20539800032023 @default.
• W2053980003 crossrefType "journal-article" @default.
• W2053980003 hasAuthorship W2053980003A5016648702 @default.
• W2053980003 hasAuthorship W2053980003A5017361094 @default.
• W2053980003 hasAuthorship W2053980003A5018369709 @default.
• W2053980003 hasAuthorship W2053980003A5026574662 @default.
• W2053980003 hasAuthorship W2053980003A5054075776 @default.
• W2053980003 hasAuthorship W2053980003A5061574089 @default.
• W2053980003 hasAuthorship W2053980003A5064306593 @default.
• W2053980003 hasAuthorship W2053980003A5086646925 @default.
• W2053980003 hasBestOaLocation W20539800031 @default.
• W2053980003 hasConcept C121608353 @default.
• W2053980003 hasConcept C126322002 @default.
• W2053980003 hasConcept C151730666 @default.
• W2053980003 hasConcept C185592680 @default.
• W2053980003 hasConcept C201750760 @default.
• W2053980003 hasConcept C2776694085 @default.
• W2053980003 hasConcept C2776755627 @default.
• W2053980003 hasConcept C2778271429 @default.
• W2053980003 hasConcept C2778670039 @default.
• W2053980003 hasConcept C2779343474 @default.
• W2053980003 hasConcept C2780394083 @default.
• W2053980003 hasConcept C28328180 @default.
• W2053980003 hasConcept C502942594 @default.
• W2053980003 hasConcept C71924100 @default.
• W2053980003 hasConcept C86803240 @default.
• W2053980003 hasConcept C95444343 @default.
• W2053980003 hasConcept C98274493 @default.
• W2053980003 hasConceptScore W2053980003C121608353 @default.
• W2053980003 hasConceptScore W2053980003C126322002 @default.
• W2053980003 hasConceptScore W2053980003C151730666 @default.
• W2053980003 hasConceptScore W2053980003C185592680 @default.
• W2053980003 hasConceptScore W2053980003C201750760 @default.
• W2053980003 hasConceptScore W2053980003C2776694085 @default.
• W2053980003 hasConceptScore W2053980003C2776755627 @default.
• W2053980003 hasConceptScore W2053980003C2778271429 @default.
• W2053980003 hasConceptScore W2053980003C2778670039 @default.
• W2053980003 hasConceptScore W2053980003C2779343474 @default.
• W2053980003 hasConceptScore W2053980003C2780394083 @default.
• W2053980003 hasConceptScore W2053980003C28328180 @default.
• W2053980003 hasConceptScore W2053980003C502942594 @default.
• W2053980003 hasConceptScore W2053980003C71924100 @default.
• W2053980003 hasConceptScore W2053980003C86803240 @default.
• W2053980003 hasConceptScore W2053980003C95444343 @default.
• W2053980003 hasConceptScore W2053980003C98274493 @default.
• W2053980003 hasIssue "5" @default.

• next